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Based on its pleiotropic effects, erythropoietin can
decrease inflammation, oxidative stress, and apoptosis.
Erythropoietin provides organ protection for the heart,
brain, and kidney in diverse preclinical animal studies,
especially models that include ischemia–reperfusion
injury and/or inflammation. However, large clinical
studies in coronary reperfusion, heart failure, stroke,
acute kidney injury, and chronic renal disease have
failed to demonstrate improved outcomes. A study in
a previous issue of Critical Care examining the ability
of erythropoietin to prevent or ameliorate acute
kidney injury in patients undergoing complex valvular
heart surgery is similarly negative. The failure of
erythropoietin in clinical studies may be due to an
inadequate dose, since the receptors responsible for
organ protection may require higher concentrations
than those responsible for erythropoiesis. However, as
has occurred in studies in sepsis and acute respiratory
distress syndrome, the negative studies probably
reflect an inadequate understanding of the complexity
of the underlying processes with multiple redundant
and interacting pathways that may differ among the
large number of different cell types involved. As tools
to understand this complexity and integrate it on an
organismal basis continue to evolve, we will develop
the ability to use erythropoietin and related
nonhematopoietic agents for organ protection.Correspondence: rgp@stanford.edu
Department of Anesthesiology, Perioperative and Pain Medicine, Stanford
University School of Medicine, 300 Pasteur Drive, Room H3589, Stanford, CA
94305-5640, USA
© 2014 Pearl; licensee BioMed Central Ltd. Th
months following its publication. After this tim
License (http://creativecommons.org/licenses/
medium, provided the original work is proper
creativecommons.org/publicdomain/zero/1.0/In a previous issue of Critical Care, Kim and colleagues
report a randomized double-blind study of the effects of
erythropoietin on acute kidney injury (AKI) in patients
undergoing complex valvular cardiac surgery [1]. AKI
occurred in 34% of patients, but there were no differ-
ences between the two groups in the incidence or sever-
ity of AKI, increases in AKI biomarkers (cystatin C and
neutrophil gelatinase-associated lipocalin) or increases in
markers of inflammation (interleukin-6 and myeloperox-
idase). Despite strong preclinical data and a previous
small clinical trial, this was a negative study. An under-
standing of the rationale for using erythropoietin for
organ protection and a review of negative clinical trials
can help us understand the information necessary for
future studies.
Erythropoietin was first identified as the major regula-
tor of erythropoiesis. The molecule was isolated in 1977,
and the gene was cloned in 1985. Recombinant human
erythropoietin was approved in the United States in
1989 for treatment of anemia associated with chronic
renal failure, and its use subsequently expanded to add-
itional indications. Erythropoietin is a 30.4 kDa glyco-
protein with 165 amino acids, and is a class I cytokine
predominantly produced by peritubular interstitial fibro-
blasts in the renal cortex and outer medulla. The major-
ity of physiological effects are due to binding to
erythropoietin receptors that are found on multiple cell
types, including renal tubular and collecting duct cells,
neurons, astrocytes, microglia, cardiomyocytes, and vas-
cular cells [2]. Following binding of erythropoietin, the
erythropoietin receptor activates JAK2, a member of the
Janus-type protein tyrosine kinase family, which then ac-
tivates multiple signaling pathways including mitogen-
activated protein kinase, phosphatidylinositol 3-kinase,
signal transducer and activator of transcription 5, and
protein kinase B. Different signaling pathways may be
activated in different cell types. Erythropoietin has pleio-
tropic cellular protective effects and can decrease in-
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kidney protection [2]. Erythropoietin improves survival in
neurons during hypoxia in cell culture, animal studies
demonstrate protection against ischemia, and initial clin-
ical trials suggested protection in ischemic stroke, but lar-
ger trials did not confirm benefits and even suggested
adverse outcomes [3]. For the heart, animal studies dem-
onstrate protection after ischemia–reperfusion, and small
clinical studies demonstrated benefit in the setting of per-
cutaneous coronary intervention for myocardial infarction.
However, large clinical trials did not demonstrate benefits
[4,5]. Similarly, trials in patients with anemia and heart
failure do not demonstrate improved outcomes and raise
concerns about increased complications [6,7]. Aggressive
use of erythropoietin for treatment of anemia in patients
with renal disease or malignancy has also failed to demon-
strate benefits [8-10].
The story of erythropoietin use for renal protection
has been similar. Animal data demonstrate protective ef-
fects, especially in the setting of ischemia–reperfusion
injury [2]. However, clinical studies in renal transplant-
ation and chronic kidney disease have been negative
[11]. AKI occurs in response to renal ischemia and in-
flammation and increases morbidity, hospital length of
stay, and short-term and long-term mortality. AKI oc-
curs in approximately one-half of patients undergoing
cardiac surgery. The anti-oxidant, anti-inflammatory,
and anti-apoptotic effects of erythropoietin suggest it
may be effective in preventing or ameliorating AKI in
this setting. In a pilot study by Oh and colleagues,
erythropoietin decreased AKI and mortality in patients
undergoing coronary artery bypass surgery [12]. How-
ever, in the study by Kim and colleagues and in another
large cardiac surgery study [13], erythropoietin did not
decrease the incidence of AKI, did not improve out-
come, and did not decrease markers of inflammation.
These negative data are consistent with the EARLYARF
trial where erythropoietin did not prevent or ameliorate
the course of AKI in ICU patients with elevated urinary
biomarkers for renal injury [14].
Erythropoietin may have failed in clinical trials due to
insufficient dose. Preclinical studies have frequently used
doses in the range of 1,000 to 5,000 IU/kg, an order of
magnitude higher than the dose of 300 IU/kg used in
many clinical studies. Although this lower dose is ad-
equate for erythropoiesis, the erythropoietin receptors
responsible for organ protection are different. Higher
doses of erythropoietin could be used but may have ad-
verse effects such as thrombosis and hypertension. One
future approach may be the use of nonhematopoietic de-
rivatives such as carbamylated erythropoietin that pro-
duce cellular and organ protection in animal studies.
Although dose may be an issue, the multiple negative clin-
ical studies suggest that our approach and understanding ofrenal, cardiac, and neurologic problems is too simplistic.
There is a complex interplay between vascular abnormalities
and inflammatory mediators, there are a myriad of different
cell types involved, and, within each individual cell, there are
complex interactions among multiple pathways that each
have redundancy. In this setting (and similarly in sepsis and
acute respiratory distress syndrome), the net impact of an
intervention that itself has pleiotropic effects becomes un-
predictable, resulting in negative clinical trials. For example,
erythropoietin is considered to be anti-inflammatory but
can worsen inflammation-induced injury in other studies
[15,16]. Effective use of erythropoietin for organ protection
will require a better understanding of the relevant processes
that occur at the cellular level [17] and the ability to pheno-
type individual patients for relevant factors that may affect
outcome. With increased knowledge, erythropoietin may
become an important weapon for preventing AKI, but it will
not be a magic bullet.
Abbreviation
AKI: Acute kidney injury.
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